Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
-
Patent number: 7595329Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.Type: GrantFiled: June 14, 2005Date of Patent: September 29, 2009Assignee: Pfizer IncInventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
-
Patent number: 7550428Abstract: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.Type: GrantFiled: August 30, 2005Date of Patent: June 23, 2009Assignee: Eli Lilly and CompanyInventors: Larry A. Larew, Nathaniel Milton, James Lawrence Sabatowski, Kenneth Philip Moder
-
Patent number: 7524860Abstract: The present invention is directed to a new class of triazolopyridine derivatives, to their use as antimicrobials, and to pharmaceuticals containing these compounds.Type: GrantFiled: September 23, 2005Date of Patent: April 28, 2009Assignee: Pfizer Inc.Inventors: David Charles Donnell Butler, Huifen Chen, Vishnumurthy Ramachandra Hegde, Chris Limberakis, Ravindra Madhukar Rasne, Richard John Sciotti, Jeremy Tyson Starr
-
Patent number: 7517909Abstract: This invention relates to certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.Type: GrantFiled: March 14, 2006Date of Patent: April 14, 2009Assignee: Pfizer IncInventors: Andrew John Thorpe, David Juergen Wustrow
-
Patent number: 7491835Abstract: This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.Type: GrantFiled: September 21, 2004Date of Patent: February 17, 2009Assignee: Pfizer IncInventors: Sean D. Donevan, Augustine Tobi Osuma, Andrew J. Thorpe, David Juergen Wustrow
-
Patent number: 7473787Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]amines of the Formula I: wherein A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30. o, p, s,t and q are as defined in the specification, their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.Type: GrantFiled: October 14, 2004Date of Patent: January 6, 2009Assignee: Pfizer IncInventors: Stanton McHardy, John A. Lowe
-
Patent number: 7473790Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: May 8, 2006Date of Patent: January 6, 2009Assignee: Pfizer Inc.Inventors: Allen Borchardt, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
-
Patent number: 7468375Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.Type: GrantFiled: April 25, 2005Date of Patent: December 23, 2008Assignee: Pfizer Inc.Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Hai Wang, Anle Yang, Chunfeng Yin, Junhu Zhang
-
Patent number: 7462600Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.Type: GrantFiled: December 21, 2005Date of Patent: December 9, 2008Assignee: Pfizer IncInventors: Louis S. Chupak, Mark E. Flanagan, Takushi Kaneko, Thomas V. Magee, Mark C. Noe, Usa Reilly
-
Patent number: 7456164Abstract: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: May 9, 2005Date of Patent: November 25, 2008Assignee: Pfizer, IncInventors: Patrick Bernardelli, Andrew Michael Cronin, Alexis Denis, Stephen Martin Denton, Henry Jacobelli, Mark Ian Kemp, Edwige Lorthiois, Fiona Rousseau, Delphine Serradeil-Civit, Fabrice Vergne
-
Patent number: 7456177Abstract: The present invention provides a compound having the structure of formula I: wherein R1 is hydrogen, (C1–C6) alkyl, unconjugated (C3–C6) alkenyl, benzyl, YC(?O)(C1–C6) alkyl or —CH2CH2—O—(C1–C4) alkyl; X is CH2 or CH2CH2; Y is (C2–C6) alkylene; Z is (CH2)m, CF2, or C(?O), where m is 0, 1 or 2; R2 and R3 are selected independently from hydrogen, halogen, —(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, and —O(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, or R2 and R3 each together with the atom to which it is connected independently form C(?O), S?O, S(?O)2, or N?O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.Type: GrantFiled: July 12, 2004Date of Patent: November 25, 2008Assignee: Pfizer Inc.Inventors: Martin P. Allen, Jotham W. Coe, Spiros Liras, Christopher J. O'Donnell, Brian T. O'Neill
-
Patent number: 7439236Abstract: The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B, Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.Type: GrantFiled: November 15, 2006Date of Patent: October 21, 2008Assignee: Pfizer IncInventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
-
Patent number: 7435728Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: June 20, 2005Date of Patent: October 14, 2008Assignee: Pfizer IncInventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 7435751Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof wherein R1 is C1-4alkyl, optionally substituted with a fluoro atom, or R1 is a cyclopropyl or cyclopropylmethyl; and R2 is methyl or ethyl. These compounds are useful as antibacterial agents.Type: GrantFiled: March 30, 2006Date of Patent: October 14, 2008Inventors: Vara Prasad Venkata Nagendra Josyula, Mikhail Gordeev, Gary Luehr
-
Patent number: 7429665Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.Type: GrantFiled: January 5, 2006Date of Patent: September 30, 2008Assignee: Pfizer IncInventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
-
Patent number: 7384773Abstract: The x-ray crystal structure of human BACE or BACE-like proteins is useful for solving the structure of other molecules or molecular complexes, and identifying and/or designing potential modifiers of human BACE activity.Type: GrantFiled: May 10, 2002Date of Patent: June 10, 2008Assignee: Pfizer IncInventors: Timothy E. Benson, Jim D. Durbin, Thomas L. Emmons, Alfredo G. Tomasselli
-
Patent number: 7381741Abstract: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.Type: GrantFiled: May 25, 2005Date of Patent: June 3, 2008Assignee: Pfizer IncInventors: John Michael Humphrey, Thomas Allen Chappie
-
Patent number: 7368571Abstract: Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.Type: GrantFiled: September 6, 2006Date of Patent: May 6, 2008Assignee: Pfizer IncInventors: Qiyue Hu, Atsuo Kuki, Dawn Marie Nowlin, Michael Bruno Plewe, Hai Wang, Junhu Zhang
-
Patent number: 7361743Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.Type: GrantFiled: August 31, 2005Date of Patent: April 22, 2008Assignee: Pfizer IncInventors: Jason G. Lewis, Sampath K Anandan, Hardwin O'Dowd, Mikhail F Gordeev, Liansheng Li
-
Patent number: 7309790Abstract: The present invention provides compounds of formula (I) wherein R1 and R2 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.Type: GrantFiled: September 28, 2004Date of Patent: December 18, 2007Assignee: Pfizer IncInventor: Paul Anthony Stupple